BioGend Therapeutics , Ltd. Current Cash

The latest current cash for 6733.TWO is $150M as of June 2026. That compares with $230M in the prior-year period — down 33.6% year over year. Investors often review this figure alongside BioGend Therapeutics , Ltd.'s historical trend and sector peers before judging valuation or financial health.

Over the past year, 6733.TWO's current cash moved from $230M to $150M — a 33.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in BioGend Therapeutics , Ltd.'s operating scale or balance-sheet position.

A current cash figure of $150M for 6733.TWO is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting 6733.TWO's current cash ($150M), review year-over-year change from $230M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack BioGend Therapeutics , Ltd.'s current cash against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.